Circulating Obestatin Levels in Normal and Type 2 Diabetic Subjects

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2010 May 27

PMID 20503481

Citations 4

Authors

D H St-Pierre

F Settanni

I Olivetti

E Gramaglia

M Tomelini

R Granata

F Prodam

A Benso

E Ghigo

F Broglio

Affiliations

Soon will be listed here.

Abstract

Background: Obestatin has been discovered as a new product of the ghrelin gene. Its physiological actions are still a matter of debate, but it seems that this peptide is likely to be involved in the control of insulin secretion and action as well as of adipocyte function. It has been already shown that obestatin secretion in humans is negatively modulated by food intake.

Aim: To clarify obestatin secretion in normal subjects and in patients with Type 2 diabetes (T2D) in basal conditions and after a standardized meal.

Subjects/methods: Five normal subjects and 5 T2D patients were studied during infusion of saline (iv for over 5 h from -120 to +180 min). A standardized lunch was served at 0 min. Obestatin, glucose, and insulin levels were assayed at -120, -90, -60, -45, -30, -15, 0, 15, 30, 45, 60, 90, 120, 150, and 180 min.

Results: From -120 to 0 min, obestatin levels in normal and T2D subjects were similar (area under the curve: 32.3+/-5.6 pg/ml/min vs 31.1+/-1.0 pg/ml/min). After the meal, circulating obestatin levels underwent a clear decrease in normal subjects (0 min: 300.6+/-34.7 pg/ml vs nadir at 60 min: 161.8+/-29.4 pg/ml; p=0.002) but not in diabetic patients (0 min: 267.2+/-16.5 pg/ml vs nadir at 180 min: 226.0+/-10.5 pg/ml).

Conclusion: This study shows that normal and diabetic subjects display similar levels of circulating obestatin in fasting condition. However patients with T2D look refractory to the inhibitory effect of meal on obestatin secretion.

Citing Articles

Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Cowan E, Burch K, Green B, Grieve D Br J Pharmacol. 2016; 173(14):2165-81.

PMID: 27111465 PMC: 4919582. DOI: 10.1111/bph.13502.

Relevance of plasma obestatin and early arteriosclerosis in patients with type 2 diabetes mellitus.

Gu P, Kang D, Wang W, Chen Y, Zhao Z, Zheng H J Diabetes Res. 2013; 2013:563919.

PMID: 24350300 PMC: 3855972. DOI: 10.1155/2013/563919.

The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling.

Agnew A, Robinson E, McVicar C, Harvey A, Ali I, Lindsay J Br J Pharmacol. 2011; 166(1):327-38.

PMID: 22035179 PMC: 3415657. DOI: 10.1111/j.1476-5381.2011.01761.x.

Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease.

Estep M, Abawi M, Jarrar M, Wang L, Stepanova M, Elariny H Obes Surg. 2011; 21(11):1750-7.

PMID: 21744131 DOI: 10.1007/s11695-011-0475-1.

References

Sun Y, Asnicar M, Smith R . Central and peripheral roles of ghrelin on glucose homeostasis. Neuroendocrinology. 2007; 86(3):215-28. DOI: 10.1159/000109094. View

Bresciani E, Rapetti D, Dona F, Bulgarelli I, Tamiazzo L, Locatelli V . Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. J Endocrinol Invest. 2006; 29(8):RC16-8. DOI: 10.1007/BF03344175. View

Depoortere I, Thijs T, Moechars D, De Smet B, Ver Donck L, Peeters T . Effect of peripheral obestatin on food intake and gastric emptying in ghrelin-knockout mice. Br J Pharmacol. 2008; 153(7):1550-7. PMC: 2437905. DOI: 10.1038/sj.bjp.0707683. View

De Smet B, Thijs T, Peeters T, Depoortere I . Effect of peripheral obestatin on gastric emptying and intestinal contractility in rodents. Neurogastroenterol Motil. 2007; 19(3):211-7. DOI: 10.1111/j.1365-2982.2006.00883.x. View

Huda M, Durham B, Wong S, Deepak D, Kerrigan D, McCulloch P . Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes (Lond). 2007; 32(1):129-35. DOI: 10.1038/sj.ijo.0803694. View

Zamrazilova H, Hainer V, Sedlackova D, Papezova H, Kunesova M, Bellisle F . Plasma obestatin levels in normal weight, obese and anorectic women. Physiol Res. 2008; 57 Suppl 1:S49-S55. DOI: 10.33549/physiolres.931489. View

Holst B, Egerod K, Schild E, Vickers S, Cheetham S, Gerlach L . GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology. 2006; 148(1):13-20. DOI: 10.1210/en.2006-0933. View

Harada T, Nakahara T, Yasuhara D, Kojima S, Sagiyama K, Amitani H . Obestatin, acyl ghrelin, and des-acyl ghrelin responses to an oral glucose tolerance test in the restricting type of anorexia nervosa. Biol Psychiatry. 2007; 63(2):245-7. DOI: 10.1016/j.biopsych.2007.04.005. View

Reinehr T, de Sousa G, Roth C . Obestatin and ghrelin levels in obese children and adolescents before and after reduction of overweight. Clin Endocrinol (Oxf). 2007; 68(2):304-10. DOI: 10.1111/j.1365-2265.2007.03042.x. View

10.

Bassil A, Haglund Y, Brown J, Rudholm T, Hellstrom P, Naslund E . Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract. Br J Pharmacol. 2006; 150(1):58-64. PMC: 2013842. DOI: 10.1038/sj.bjp.0706969. View

11.

Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W . Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun. 2006; 351(1):21-5. DOI: 10.1016/j.bbrc.2006.09.141. View

12.

Beasley J, Ange B, Anderson C, Miller Iii E, Holbrook J, Appel L . Characteristics associated with fasting appetite hormones (obestatin, ghrelin, and leptin). Obesity (Silver Spring). 2008; 17(2):349-54. PMC: 2855218. DOI: 10.1038/oby.2008.551. View

13.

Fontenot E, deVente J, Seidel E . Obestatin and ghrelin in obese and in pregnant women. Peptides. 2007; 28(10):1937-44. DOI: 10.1016/j.peptides.2007.08.005. View

14.

Haider D, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M . Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2006; 92(3):1168-71. DOI: 10.1210/jc.2006-1839. View

15.

Zhang J, Ren P, Avsian-Kretchmer O, Luo C, Rauch R, Klein C . Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science. 2005; 310(5750):996-9. DOI: 10.1126/science.1117255. View

16.

Qi X, Li L, Yang G, Liu J, Li K, Tang Y . Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2007; 66(4):593-7. DOI: 10.1111/j.1365-2265.2007.02776.x. View

17.

Lippl F, Erdmann J, Lichter N, Tholl S, Wagenpfeil S, Adam O . Relation of plasma obestatin levels to bmi, gender, age and insulin. Horm Metab Res. 2008; 40(11):806-12. DOI: 10.1055/s-2008-1081503. View

18.

Gourcerol G, Coskun T, Craft L, Mayer J, Heiman M, Wang L . Preproghrelin-derived peptide, obestatin, fails to influence food intake in lean or obese rodents. Obesity (Silver Spring). 2007; 15(11):2643-52. DOI: 10.1038/oby.2007.316. View

19.

Guo Z, Zheng X, Qin Y, Hu J, Chen S, Zhang Z . Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metab. 2007; 92(5):1875-80. DOI: 10.1210/jc.2006-2306. View

20.

Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V . Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes. 2007; 57(4):967-79. DOI: 10.2337/db07-1104. View